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Neutrophil trafficking to inflamed tissues requires the integration of multiple chemoattractant guidance
signals. In this issue of Immunity, Chou et al. (2010) demonstrate that collaborative ‘‘cascades’’ of chemoat-
tractant mediators control neutrophil recruitment to arthritic joints in mice.Chemoattractants represent an essential
group of molecular guidance signals that
choreograph the transit of leukocytes
out of the mainstream of blood and into
tissues at sites of inflammation. Neutro-
phils are uniquely sensitive to a vast array
of chemoattractants including comple-
ment fragments (C5a, C3a), lipid media-
tors (LTB4, PAF), a multitude of chemo-
kines (in mice, MIP-1a, MIP-1b, MIP-2,
KC, and others), as well as exogenous
mediators produced by pathogens (N-for-
mylated peptides). The ability to respond
to multiple chemoattractants with seem-
ingly overlapping functionsmay represent
a mechanism to ensure timely neutrophil
recruitment during host defense. Alterna-
tively, the apparent redundancy among
chemoattractant signals may simply
represent a default hypothesis resulting
from a lack of evidence for nonredundant
functions.
A multitude of chemokines can direct
neutrophil recruitment, including (in mice)
ligands of the twomain chemokine recep-
tors expressed on neutrophils, CCR1
and CXCR2. Studies using deletion or
blocking strategies to investigate the
roles of CCR1 or CXCR2 in vivo have
historically resulted in only partial inhibi-
tion of neutrophil recruitment, leading
many to presume that these receptors
(and their chemokine ligands) possess
overlapping functions (Jacobs et al.,
2010). However, such observations may
also be explained by the alternate hypoth-
esis that precise temporal and/or spatial
control of chemoattractant production
may yield unique roles for different che-
mokines and their receptors. Furthermore,
signals from other mediators such as
lipids and complement fragments must
be integrated with chemokines to control
neutrophil trafficking.148 Immunity 33, August 27, 2010 ª2010 ElsChou et al. (2010) test the hypothesis
that neutrophil recruitment into inflamed
joints is controlled by temporally distinct
cascades of chemoattractants, in which
the response to one chemoattractant
initiates pathways that lead to the expres-
sion of additional mediators, yielding
nonredundant functions for each guid-
ance signal (Chou et al., 2010). Previous
investigations by the same group re-
vealed that the lipid chemoattractant
LTB4 and its receptor BLT1 are critical
for neutrophil infiltration and disease
pathology during autoantibody-induced
arthritis (Kim et al., 2006). Interestingly,
the LTB4-BLT1 axis was required to
attract a first wave of neutrophils, but
once these initial responders had infil-
trated into the joint, further neutrophil
recruitment proceeded independently of
BLT1. In this issue, Chou et al. (2010)
report that neutrophils recruited via BLT1
signaling early in arthritogenesis produce
cytokines including IL-1b, which act on
resident cells within the joint to induce
the expression of chemokine ligands of
CCR1 (including MIP-1a, MIP-1b, and
RANTES), followed soon after by CXCR2-
ligands (including KC, MIP-2, and LIX)
(Figure 1).
Together with the temporally defined
pattern of chemokine expression, the
authors also found that CCR1 and CXCR2
mediated temporally distinct, nonredun-
dant roles during arthritis development.
By using CCR1-, CXCR2-, as well as
doubly-deficient mice, it was found that
CCR1 provided the guidance signals for
early neutrophil recruitment, whereas
CXCR2promoted later and sustained infil-
tration. Previous studies have demon-
strated that cytokine-mediated control of
chemokine and receptor expression also
serves to diversify guidance signals overevier Inc.time.During chronic inflammation, neutro-
phils begin to express new receptors
and respond to chemokines normally
thought to recruit monocytes (such as
MCP-1) in response to cytokines such
as IFN-g (Bonecchi et al., 1999; Johnston
et al., 1999). Findings such as these raise
the interesting question of whether all
neutrophils possess the ability to adapt
to changing chemoattractant environ-
ments, or whether continued infiltration
represents the progressive recruitment
of phenotypically and functionally unique
subsets of neutrophils. For example,
BLT1-expressing neutrophils may be
particularly adept at IL-1 production, posi-
tioning them as a unique sentinel popula-
tion that stimulates the recruitment of
further neutrophil subsets. Indeed, mice
have been reported to possess multiple
neutrophil subsets with unique surface
receptor phenotypes and effector func-
tions (Tsuda et al., 2004). Furthermore,
the existence of a putative population of
tissue-resident or perhaps continuously
recirculating ‘‘pioneer’’ neutrophils (for
which there is currently no direct evi-
dence) may explain why many studies
including this have struggled to under-
stand how the very first neutrophils arrive
at sites of inflammation.
The study by Chou et al. (2010) high-
lights the underappreciated complexity
of chemical guidance signals that direct
neutrophil trafficking and challenges
our concepts of biological redundancy
among inflammatory mediators. In addi-
tion to the temporally unique roles for
BLT1, CCR1, CXCR2, and their ligands
identified in this study, further layers of
complexity exist among chemoattrac-
tants that are spatially separated in vivo.
Leukocytes must traffic through multiple
microenvironments en route to sites of
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Figure 1. Lipid-Cytokine-Chemokine Cascade Choreographs Neutrophil Recruitment into
the Inflamed Joint
After transfer of autoantibody-containing serum from K/BxN transgenic mice into recipients, immune
complexes deposit within joints and initiate an inflammatory response. Initially, production of the lipid
chemoattractant LTB4 by synovial leukocytes (mast cells, macrophages, neutrophils) attracts neutrophils
into the joint via signaling through BLT1 receptors. Infiltrating neutrophils release IL-1b, which stimulates
resident cells (including endothelium, macrophages, and synoviocytes) to express chemokines that
amplify and sustain neutrophil recruitment. Expression of CC-chemokines (including MIP-1a, MIP-1b,
and RANTES) recruits neutrophils via CCR1 signaling during the initiation phase of arthritis. CXC-chemo-
kines (including KC, MIP-2, and LIX) sustain neutrophil recruitment during the maintenance phase of
disease via signaling though CXCR2.
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Previewsinflammation, each presenting distinct
gradients of chemoattractants expressed
by different cell types along the way.
When faced with opposing gradients of
different chemoattractants, neutrophils
preferentially migrate toward end-target
chemoattractants (C5a, N-fomylated
peptides) and away from intermediary
chemoattractants (chemokines, LTB4)
(Foxman et al., 1997). The ability to
perform such cellular decision-making
involves intracellular signal hierarchies
that allow end-target chemoattractant
signaling to dominate over other direc-
tional cues (Heit et al., 2008). Indeed,
during autoantibody-induced arthritis,
disruption of the neutrophils’ ability topreferentially migrate toward end-target
chemoattractants by deletion of PTEN
within neutrophils attenuated recruitment
into joints as well as clinical disease
(Heit et al., 2008).
The existence of a positive-feedback
loop involving lipid-cytokine-chemokine
cascades that drive neutrophil recruit-
ment and development of arthritis raises
a serious problem for the host: how can
this self-perpetuating process be turned
off? A key avenue for future research will
involve discovering how these mediator
cascades are modulated and/or downre-
gulated to initiate resolution of inflamma-
tion, or alternatively, how dysregulation
of these cascades results in sustainedImmunity 33inflammation and disease. Events such
as lipid mediator ‘‘class switching’’
(describing the gradual reduction of proin-
flammatory prostaglandins and leukotri-
enes in favor of proresolution mediators
such as resolvins and protectins) may
stimulate downstream ‘‘cascades’’ of
cytokines and chemokines that actually
reduce neutrophil infiltration and con-
tribute to resolution of inflammation
(Serhan et al., 2008). Furthermore, under-
standing how inappropriate or overexu-
berant chemoattractant cascades con-
tribute to disease pathogenesis may
reveal targets for the development of
anti-inflammatory therapies. The findings
by Chou et al. (2010) suggest that thera-
pies aimed at chemokines or their recep-
tors present the challenge of trying to
hit a moving target, whereas blockade of
factors upstream in the lipid-cytokine-
chemokine cascade may be of greater
benefit. This evidence may explain, in
part, the effectiveness of anticytokine
therapies in human rheumatoid arthritis.
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